Heart Failure Clinical Trial

Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%

Summary

This is a randomised, double-blind, placebo-controlled, multi-center sequential phase 2b and Phase 3 study to evaluate the efficacy and safety of AZD4831 administered for up to 48 Weeks in participants with heart failure with left ventricular ejection fraction > 40%. The study will consist of 2 separate parts, Part A and Part B, approximately 660 participants will be randomised in Part A, 820 in Part B.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Part A

≥ 40 to ≤ 85 years of age, at the time of signing the informed consent.
Documented stable symptomatic HF (New York Heart Association Class II-IV) for at least 1 month at Screening (Visit 1) (transient HF in the setting of an MI does not qualify), with a medical history of typical symptoms of HF and receiving optimal therapy for HF as determined by the health-care physician.
LVEF > 40% at Screening (Visit 1). All participants will undergo a local echocardiogram at the Screening (Visit 1) with central reading to confirm the LVEF > 40% eligibility criteria before randomisation.
6MWD ≥ 30 meters and ≤ 400 meters at Screening (Visit 1) and Randomisation (Visit 3). Difference in 6MWD between Screening and Randomisation must be < 50 meters.
KCCQ-TSS ≤ 90 points at Screening (Visit 1) and Randomisation (Visit 3)
NT-proBNP ≥ 250 pg/mL (sinus rhythm) or ≥ 500 pg/mL (atrial fibrillation/flutter) at Screening (Visit 1) for patients with BMI ≤30 kg/m2.

NT-proBNP ≥ 200 pg/mL (sinus rhythm) or ≥ 400 pg/mL (atrial fibrillation/flutter) at Screening (Visit 1) for patients with BMI > 30 kg/m2.

The ECG performed at Screening should be used for heart rhythm evaluation.

7.At least one of the following:

Structural heart disease, ie, LA enlargement and/or left ventricular hypertrophy at the echocardiogram performed at Screening (Visit 1). Left atrial enlargement is defined by at least 1 of the following: LA width (diameter) ≥ 3.8 cm or LA length ≥ 5.0 cm, or LA area ≥ 20 cm2 or LA volume ≥ 55 mL or LAVI > 34 mL/m2. Left ventricular hypertrophy is defined by septal thickness or posterior wall thickness ≥ 1.1 cm or LVMI > 95 g/m2 in women and > 115 g/m2 in men.
Spectral tissue Doppler echocardiography - E/e' ratio (average of septal and lateral) ≥ 13 at rest at the echocardiogram performed at Screening (Visit 1).
Indirectly estimated elevation of PASP by TRmax velocity > 2.8 m/s (280 cm/s) (PASP > 35 mmHg) at the echocardiogram performed at Screening (Visit 1) OR directly measured pulmonary capillary wedge pressure > 15 mmHg at rest within the past 12 months or > 25 mmHg at exercise documented by right heart catheterisation within 12 months prior to Screening (Visit 1).

HF decompensation within 6 months before Randomisation (Visit 3), defined as hospitalisation for HF or IV diuretic treatment for HF during an urgent, unscheduled visit without hospitalisation.

8.Body mass index ≥ 18.0 kg/m2 and ≤ 45.0 kg/m2

9.Male or female of non-childbearing potential.

Part B

Participant must be ≥ 40 to ≤ 85 years of age, at the time of signing the informed consent.
Documented diagnosis of symptomatic HF (NYHA class II-IV) at Screening (Visit 1), and a medical history of typical symptoms/signs of heart failure ≥ 6 weeks before Screening (Visit 1), and receiving optimal therapy for HF as determined by the health-care physician, with at least intermittent need for diuretic treatment.

LVEF >40% and evidence of structural heart disease (ie, left ventricular hypertrophy or

left atrial enlargement [defined by at least one of the following:LA enlargement and/or left ventricular hypertrophy at the echocardiogram

performed at Screening (Visit 1). Left atrial enlargement is defined by at least 1 of the following: LA width

(diameter) ≥ 3.8 cm or LA length ≥ 5.0 cm, or LA area ≥ 20 cm2 or LA volume ≥ 55 mL or LAVI > 34

mL/m2. Left ventricular hypertrophy is defined by septal thickness or posterior wall thickness ≥ 1.1 cm or

LVMI > 95 g/m2 in women and > 115 g/m2 in men.]) documented by the most recent echocardiogram, or cardiac

magnetic resonance imaging within the last 12 months prior to Screening (Visit 1). If no

echocardiogram is available, it can be performed at Screening (Visit 1).

6MWD ≥ 30 meters and ≤ 400 meters at Screening (Visit 1) and Randomisation (Visit 2). Difference in 6MWD between Screening and Randomisation must be < 50 meters
KCCQ-TSS ≤ 90 points at Screening (Visit 1) and Randomisation (Visit 2).
NT-proBNP ≥ 250 pg/mL (sinus rhythm) or ≥ 500 pg/mL (atrial fibrillation/flutter) at Screening (Visit 1) for patients with BMI ≤ 30 kg/m2. NT-proBNP ≥ 200 pg/mL (sinus rhythm) or ≥ 400 pg/mL (atrial fibrillation/flutter) at Screening (Visit 1) for patients with BMI > 30 kg/m2. The ECG performed at Screening should be used for heart rhythm evaluation
Body mass index ≥ 18.0 kg/m2 and ≤ 45.0 kg/m2
Male or female of non-childbearing potential.

Exclusion Criteria:

Part A

1 eGFR < 30 mL/min/1.73m2 (Chronic Kidney Disease-Epidemiology Collaboration formula) at Screening (Visit 1).

2. Systolic blood pressure < 90 mmHg or ≥ 160 mmHg if not on treatment with ≥ 3 blood pressure lowering medications or ≥ 180 mmHg irrespective of treatments at Randomisation

3. Heart rate > 110 bpm or < 50 bpm at Randomisation

4. Life expectancy < 3 years due to other reasons than cardiovascular disease.

5. History or ongoing allergy/hypersensitivity reactions to drugs (including but not limited to rash, angioedema, acute urticaria).

6. Presence of any disease or condition rather than HF constituting the main reason for limiting the ability to exercise/reduced exercise capacity.

7. Current decompensated HF and/or NT-proBNP > 5000 pg/mL at Screening (Visit 1)

8. Documented history of ejection fraction ≤ 40%.i.e. HF with recovered ejection fraction. Transient ejection fraction decrease e.g. in the setting of an MI does not apply

9. Any planned cardiovascular procedure (eg, coronary revascularisation, ablation of atrial fibrillation/flutter, valve repair/replacement, aortic aneurysm surgery, etc).

10. Any cardiac event (eg, myocardial infarction, unstable angina), coronary revascularisation (percutaneous coronary intervention or coronary artery bypass grafting), ablation of atrial fibrillation/flutter, valve repair/replacement, implantation of a cardiac resynchronisation therapy device within 12 weeks prior to Screening (Visit 1) or between Screening and Randomisation. Patients who underwent a successful atrial fibrillation/flutter cardioversion, can be enrolled in the study after 4 weeks.

14. Hb < 110 g/L (male) and < 100 g/L (female) or iron-deficiency with/without anaemia requiring ongoing or planned IV iron treatment.

15. Participants with hyperthyroidism, uncontrolled hypothyroidism (including but not limited to TSH ≥10 mIU/mL), or any clinically significant thyroid disease as judged by the investigator.

18. ALT or AST ≥ 2 × ULN at Screening (Visit 1).

19. Pulmonary arterial hypertension, chronic pulmonary embolism, severe pulmonary disease including COPD (ie, requiring home oxygen, chronic nebulizer therapy or chronic oral steroid therapy, or hospitalization for exacerbation of COPD requiring ventilatory support within 12 months prior to Screening (Visit 1).

20. Any active infection requiring oral, intravenous or intramuscular treatment at Screening (Visit 1) and/or at Randomisation.

23 Any signs or confirmation of COVID-19 infection:

Suspected (as judged by PI) or confirmed COVID-19 within the last 2 weeks prior to Screening (Visit 1) or at Randomisation.

Hospitalisation for COVID-19 within the last 12 weeks prior to Screening (Visit 1).

24. Any concomitant medications known to be a potent CYP3A4 inducers or inhibitors, eg, itraconazole, rifampicin, clarithromycin, or propylthiouracil

29. Previous enrolment and randomisation in the present study. (Participants who where screened and screen failed and not randomised in Part A can be screened for possible entry to Part B).

All exclusion criteria in Part A are applicable to Part B with the following exceptions:

Exclusion criteria 4; 19

Exclusion Criteria specific for Part B only [criteria numeration for Part B]

4. Life expectancy < 2 years due to other reasons than cardiovascular disease.

11. HF due to any of the following: known infiltrative cardiomyopathy (eg, amyloid, sarcoid, lymphoma, endomyocardial fibrosis), active myocarditis, constrictive pericarditis, cardiac tamponade, known genetic hypertrophic cardiomyopathy or obstructive hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D), or uncorrected primary valvular disease.

18. Primary pulmonary hypertension, chronic pulmonary embolism, severe pulmonary disease including COPD (ie, requiring home oxygen, chronic nebulizer therapy or chronic oral steroid therapy, or hospitalization for exacerbation of COPD requiring ventilatory support within 12 months prior to Screening [Visit 1]).

Study is for people with:

Heart Failure

Phase:

Phase 2

Estimated Enrollment:

711

Study ID:

NCT04986202

Recruitment Status:

Completed

Sponsor:

AstraZeneca

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 169 Locations for this study

See Locations Near You

Research Site
Alexander City Alabama, 35010, United States
Research Site
Little Rock Arkansas, 72205, United States
Research Site
Sacramento California, 95821, United States
Research Site
Miami Beach Florida, 33140, United States
Research Site
Miami Florida, 33144, United States
Research Site
Ocala Florida, 34471, United States
Research Site
Evanston Illinois, 60208, United States
Research Site
Hazel Crest Illinois, 60429, United States
Research Site
Shreveport Louisiana, 71105, United States
Research Site
Baltimore Maryland, 21229, United States
Research Site
Saint Louis Missouri, 63136, United States
Research Site
Buffalo New York, 14215, United States
Research Site
New York New York, 10019, United States
Research Site
Rosedale New York, 11422, United States
Research Site
Chapel Hill North Carolina, 27599, United States
Research Site
Pinehurst North Carolina, 28374, United States
Research Site
Cleveland Ohio, 44195, United States
Research Site
Philadelphia Pennsylvania, 19107, United States
Research Site
Knoxville Tennessee, 37916, United States
Research Site
Tullahoma Tennessee, 37388, United States
Research Site
Norfolk Virginia, 23510, United States
Research Site
Bedford Park , 5042, Australia
Research Site
Chermside , 4032, Australia
Research Site
Concord , 2139, Australia
Research Site
Frankston , 3199, Australia
Research Site
Aalst , 9300, Belgium
Research Site
Dendermonde , 9200, Belgium
Research Site
Hasselt , 3500, Belgium
Research Site
Huy , 4500, Belgium
Research Site
Kortrijk , 8500, Belgium
Research Site
Leuven , 3000, Belgium
Research Site
Roeselare , 8800, Belgium
Research Site
Brasilia , 72145, Brazil
Research Site
Campina Grande do Sul , 83430, Brazil
Research Site
Campinas , 13060, Brazil
Research Site
Campinas , 13092, Brazil
Research Site
Canoas , 92425, Brazil
Research Site
Curitiba , 80730, Brazil
Research Site
Porto Alegre , 90035, Brazil
Research Site
Ribeirão Preto , 14026, Brazil
Research Site
Ribeirão Preto , 14051, Brazil
Research Site
Rio de Janeiro , 22061, Brazil
Research Site
São Paulo , 01228, Brazil
Research Site
Blagoevgrad , 2700, Bulgaria
Research Site
Pleven , 5804, Bulgaria
Research Site
Plovdiv , 4003, Bulgaria
Research Site
Sofia , 1202, Bulgaria
Research Site
Sofia , 1309, Bulgaria
Research Site
Sofia , 1407, Bulgaria
Research Site
Sofia , 1431, Bulgaria
Research Site
Sofia , 1527, Bulgaria
Research Site
Sofia , 1606, Bulgaria
Research Site
Sofia , 1784, Bulgaria
Research Site
Varna , 9000, Bulgaria
Research Site
Guelph Ontario, N1H 1, Canada
Research Site
Newmarket Ontario, L3Y 2, Canada
Research Site
Ottawa Ontario, K1Y 4, Canada
Research Site
Toronto Ontario, M6G 1, Canada
Research Site
Waterloo Ontario, N2T 0, Canada
Research Site
York Ontario, M9N 1, Canada
Research Site
Chicoutimi Quebec, G7H 7, Canada
Research Site
Trois-Rivières Quebec, G9A 4, Canada
Research Site
Brno , 625 0, Czechia
Research Site
Broumov , 55001, Czechia
Research Site
Jaromer , 551 0, Czechia
Research Site
Kolin , 280 0, Czechia
Research Site
Louny , 440 0, Czechia
Research Site
Plzen , 320 0, Czechia
Research Site
Praha 2 , 121 1, Czechia
Research Site
Praha , 110 0, Czechia
Research Site
Pribram , 261 0, Czechia
Research Site
Zlin , 760 0, Czechia
Research Site
Copenhagen O , 2100, Denmark
Research Site
Hvidovre , 2650, Denmark
Research Site
København NV , 2400, Denmark
Research Site
København , 2300, Denmark
Research Site
Roskilde , 4000, Denmark
Research Site
Viborg , 8800, Denmark
Research Site
Århus N , 8200, Denmark
Research Site
Bayonne , 64100, France
Research Site
Dijon Cedex , 21079, France
Research Site
La Tronche , 38043, France
Research Site
Le Coudray Cedex , 28630, France
Research Site
Montauban , 82017, France
Research Site
Montpellier Cedex , 34295, France
Research Site
Paris , 75010, France
Research Site
Paris , 75015, France
Research Site
Pierre Benite , 69495, France
Research Site
Rennes Cedex 9 , 35033, France
Research Site
Saint Brieuc , 22027, France
Research Site
Toulon , 83100, France
Research Site
Toulouse Cedex 9 , 31059, France
Research Site
TOURCOING cedex , 59208, France
Research Site
Balatonfüred , 8230, Hungary
Research Site
Budapest , 1096, Hungary
Research Site
Budapest , 1122, Hungary
Research Site
Nyíregyháza , 4400, Hungary
Research Site
Fukui-shi , 910-8, Japan
Research Site
Higashiohmi-shi , 527-8, Japan
Research Site
Iwakuni-shi , 740-8, Japan
Research Site
Kanazawa-shi , 920-8, Japan
Research Site
Kasugai-shi , 487-0, Japan
Research Site
Kishiwada-shi , 596-0, Japan
Research Site
Kure-shi , 737-0, Japan
Research Site
Kyoto-shi , 612-8, Japan
Research Site
Matsumoto-shi , 390-8, Japan
Research Site
Minami-ku , 861-4, Japan
Research Site
Nagano , 399-8, Japan
Research Site
Naha , 902-8, Japan
Research Site
Oita-shi , 870-8, Japan
Research Site
Omihachiman-shi , 523-0, Japan
Research Site
Otaru-shi , 047-8, Japan
Research Site
Sagamihara-shi , 252-5, Japan
Research Site
Toshima-ku , 171-0, Japan
Research Site
Ueda-shi , 386-8, Japan
Research Site
Uwajima-shi , 798-8, Japan
Research Site
Yokohama-shi , 245-8, Japan
Research Site
Amsterdam , 1081 , Netherlands
Research Site
Den Bosch , 5223 , Netherlands
Research Site
Den Haag , 2545 , Netherlands
Research Site
Deventer , 7416 , Netherlands
Research Site
Heerlen , 6419 , Netherlands
Research Site
Bydgoszcz , 85-07, Poland
Research Site
Lublin , 20-04, Poland
Research Site
Rzeszow , 35-05, Poland
Research Site
Skierniewice , 96-10, Poland
Research Site
Tarnów , 33-10, Poland
Research Site
Tczew , 83-11, Poland
Research Site
Tychy , 43-10, Poland
Research Site
Warszawa , 02-67, Poland
Research Site
Warszawa , 02-75, Poland
Research Site
Warszawa , 04-74, Poland
Research Site
Wołomin , 05-20, Poland
Research Site
Aramil , 62400, Russian Federation
Research Site
Kemerovo , 65000, Russian Federation
Research Site
Moscow , 11999, Russian Federation
Research Site
Moscow , 12120, Russian Federation
Research Site
Moscow , 12155, Russian Federation
Research Site
Novosibirsk , 63005, Russian Federation
Research Site
Perm , 61400, Russian Federation
Research Site
St Petersburg , 19506, Russian Federation
Research Site
Tver , 17003, Russian Federation
Research Site
Banska Bystrica , 974 0, Slovakia
Research Site
Bratislava , 821 0, Slovakia
Research Site
Brezno , 977 0, Slovakia
Research Site
Kosice , 04022, Slovakia
Research Site
Kosice , 044 2, Slovakia
Research Site
Nitra , 949 0, Slovakia
Research Site
Presov , 080 0, Slovakia
Research Site
Göteborg , 413 4, Sweden
Research Site
Jönköping , 551 8, Sweden
Research Site
Lund , 222 2, Sweden
Research Site
Norrköping , 603 7, Sweden
Research Site
Stockholm , 118 8, Sweden
Research Site
Stockholm , 171 7, Sweden
Research Site
Stockholm , 18288, Sweden
Research Site
Örebro , 701 8, Sweden
Research Site
Kaohsiung , 807, Taiwan
Research Site
Kaohsiung , 81362, Taiwan
Research Site
Kaohsiung , 833, Taiwan
Research Site
Taichung , 40201, Taiwan
Research Site
Taichung , 40447, Taiwan
Research Site
Taichung , 40705, Taiwan
Research Site
Tainan , 70403, Taiwan
Research Site
Tainan , 710, Taiwan
Research Site
Taipei 112 , , Taiwan
Research Site
Taipei City , 110, Taiwan
Research Site
Taipei , 100, Taiwan
Research Site
Taoyuan , 333, Taiwan
Research Site
Eskisehir , 26480, Turkey
Research Site
Izmir , 35340, Turkey

How clear is this clinincal trial information?

Study is for people with:

Heart Failure

Phase:

Phase 2

Estimated Enrollment:

711

Study ID:

NCT04986202

Recruitment Status:

Completed

Sponsor:


AstraZeneca

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.